Peer-reviewed veterinary case report
Use of antifibrinolytic drugs for bleeding in cats and outcomes
By Wahldén, Lotta et al.·Published in Journal of the American Animal Hospital Association·2023·From AniCura Regiondjursjukhuset Bagarmossen·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of Therapeutic Use of Antifibrinolytics in Cats.
- Species:
- cat
Plain-English summary
A group of 35 cats received antifibrinolytic medications, tranexamic acid (TXA) or epsilon aminocaproic acid (EACA), to help stop bleeding during various medical situations, including surgery and injuries. About half of the cats survived after treatment, but some experienced side effects. The doses varied widely, with TXA typically given at 10 mg/kg and EACA at 50 mg/kg. While the study highlighted the potential benefits of these medications, it also noted that more research is needed to better understand their safety and effectiveness in cats.
People also search for: cat bleeding treatment · tranexamic acid for cats · EACA side effects in cats
Abstract
Limited data are available regarding the use of the antifibrinolytic drugs tranexamic acid (TXA) and epsilon aminocaproic acid (EACA) in cats. This study aimed to evaluate the indications for the use of TXA and EACA in cats and to describe dosing regimens used, occurrence of adverse events, and patient outcomes. This was a retrospective multicenter study. Medical databases were searched for feline patients billed for TXA or EACA between 2015 and 2021. Thirty-five cats met the inclusion criteria; 86% received TXA and 14% received EACA. The most common indication was nontraumatic hemorrhage (54%), followed by traumatic hemorrhage (17%) and elective surgery (11%). The median dose was 10 mg/kg for TXA and 50 mg/kg for EACA. Overall, 52% of cats survived to discharge. Potential adverse events were noted in 7/35 (20%) patients. Of these, 29% survived to discharge. No standardized dosing regimen was identified; rather, dose, dosing interval, and duration of administration varied markedly between patients. Administration was potentially associated with severe adverse events, although the retrospective design makes it difficult to establish a causal association with antifibrinolytic use. This study provides a base for future prospective studies by giving an insight into the use of antifibrinolytic drugs in cats.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/37432789/